Anti-CD47-CLDN18.2 bispecific antibodies and uses thereof

A bispecific antibody targeting CD47 and CLDN18.2 with defined CDR sequences addresses the challenges of existing antibodies by enhancing cancer cell targeting and tumor inhibition while minimizing side effects on normal cells.

JP2024541118AActive Publication Date: 2024-11-06DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO LTD +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024547805
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-19
Filing Date
2022-03-21
Publication Date
2024-11-06
Estimated Expiration
2042-03-21

AI Technical Summary

Technical Problem

Existing anti-CD47 antibodies face challenges such as high expression on normal cells like red blood cells, leading to adverse side effects and the need for high doses, and there is a need for improved bispecific antibodies targeting CD47 and CLDN18.2 for cancer therapy.

Method used

Development of a bispecific antibody comprising specific antigen-binding moieties for CD47 and CLDN18.2 with defined CDR sequences, designed to minimize binding to red blood cells and enhance targeting of cancer cells, potentially inducing phagocytosis through the CD47-SIRPα pathway.

Benefits of technology

The bispecific antibody effectively blocks CD47-SIRPα interaction on cancer cells, induces phagocytosis, and demonstrates enhanced binding and tumor inhibition, reducing tumor growth with minimal impact on normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541118000001_ABST
    Figure 2024541118000001_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biopharmaceuticals. In particular, the present invention relates to an anti-CD47-CLDN18.2 bispecific antibody and its use.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to Chinese Patent Application No. 202111214360.8, entitled "Anti-CD47-CLDN18.2 Bispecific Antibody and Use Thereof," filed on October 19, 2021, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to the field of biopharmaceuticals. In particular, the present invention relates to an anti-CD47-CLDN18.2 bispecific antibody and its use. [Background technology]

[0003] CD47 is a transmembrane glycoprotein that is widely expressed on the cell surface and belongs to the immunoglobulin superfamily. It can mediate a series of reactions such as cell apoptosis, proliferation, and immunity by interacting with signal regulatory protein α (SIRPα), thrombospondin-1 (TSP1), and integrins. It has been confirmed that blocking the CD47-SIRPα pathway with anti-CD47 antibodies can effectively mediate phagocytosis of tumor cells, thereby inhibiting the proliferation of various hematological and solid tumors in vivo. However, CD47 is not only highly expressed on tumor cells, but also expressed in large amounts on normal cells, such as red blood cells, and CD47-targeting therapy may cause undesirable side effects. Some anti-CD47 antibodies disclosed in the prior art (see, e.g., US20160304609) not only bind to red blood cells and cause severe anemic reactions, but also require dosages of up to 30 mg / kg for administration, and these properties pose significant challenges to the clinical application of anti-CD47 antibodies.

[0004] CLDN18, a member of the Claudins protein family, was discovered in 1998 by Shoichiro Tsukita et al. and is an important molecule that constitutes the tight junction of epithelial cells, determines the permeability of epithelial cells, and also plays a role in preventing the diffusion of cell membrane surface proteins and lipids (Gunzel, D. and AS Yu (2013) Physiol Rev 932: 525-569). The human CLDN18 gene has two different exons 1, which undergo alternative post-transcriptional splicing to ultimately generate two protein subtypes, CLDN18.1 and CLDN18.2, which have different sequences only at the N-terminus. Due to its expression specificity in tumor cells and normal tissues, CLDN18.2 is currently a highly potential target of antitumor drugs. WO 2016165762A1 discloses an anti-CLDN18.2 antibody, IMAB362 (Zolbetuximab), which showed a significant survival benefit over standard chemotherapy (13.2 vs. 8.4 months) in a phase II clinical trial for gastric cancer, with the advantage being more pronounced in patients with high CLDN18.2 expression.

[0005] WO 2021003082A1 discloses an anti-CLDN18.2 and CD47 bispecific antibody, which does not substantially bind to human erythrocytes. However, there is still a need to develop new bispecific antibodies targeting CLDN18.2 and CD47 to provide further possibilities for cancer treatment. Summary of the Invention

[0006] In one aspect, the invention provides a bispecific antibody, comprising a first antigen binding moiety that binds CD47 and a second antigen binding moiety that binds CLDN18.2, wherein said first antigen binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein said heavy chain variable region comprises 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO:4, 2) an HCDR2 comprising the amino acid sequence of SEQ ID NO:5, and 3) an HCDR3 comprising the amino acid sequence of SEQ ID NO:6, and said light chain variable region comprises 1) an LCDR1 comprising the amino acid sequence of SEQ ID NO:7, 2) an LCDR2 comprising the amino acid sequence of SEQ ID NO:8, and 3) an LCDR3 comprising the amino acid sequence of SEQ ID NO:9.

[0007] In some embodiments, the second antigen-binding portion comprises an immunoglobulin single variable domain (VHH) that binds to CLDN18.2. Preferably, the immunoglobulin single variable domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:13, a CDR2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR3 comprising the amino acid sequence of SEQ ID NO:15.

[0008] In a further aspect, the present invention provides an isolated polynucleotide, which encodes a bispecific antibody of the present invention.

[0009] The present invention further provides an expression vector, which comprises a polynucleotide of the present invention.

[0010] In another aspect, the present invention provides a host cell, which comprises a polynucleotide or an expression vector of the invention.

[0011] The present invention further relates to an antibody conjugate, which comprises a bispecific antibody of the invention conjugated to at least one therapeutic agent.

[0012] In a further aspect, the present invention relates to a pharmaceutical composition, which comprises the bispecific antibody or antibody conjugate of the invention and a pharma- ceutically acceptable carrier agent.

[0013] The present invention further relates to the use of a bispecific antibody, an antibody conjugate or a pharmaceutical composition of the invention in the manufacture of a medicament for treating cancer. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 shows the schematic structure of the anti-CD47-CLDN18.2 bispecific antibody. [Figure 2ab] FIG. 1 shows the binding activity of anti-CD47-CLDN18.2 bispecific antibody to CD47 on red blood cells. [Figure 3ab] 3A and 3B show the binding activity of anti-CD47-CLDN18.2 bispecific antibodies to tumor cells expressing single and dual targets, in which FIG. 3A shows the binding activity of anti-CD47-CLDN18.2 bispecific antibodies to NUGC-4 cells and FIG. 3B shows the binding activity of anti-CD47-CLDN18.2 bispecific antibodies to hCLDN18.2-NUGC-4 cells. [Figure 4abc] 4A and 4B show the ability of anti-CD47-CLDN18.2 bispecific antibody to block the binding of human CD47 to the receptor SIRPα in tumor cells expressing single and dual targets, where FIG. 4A shows the ability of anti-CD47-CLDN18.2 bispecific antibody to block the binding of human CD47 to the receptor SIRPα in NUGC-4 cells, and FIG. 4B and FIG. 4C show the ability of anti-CD47-CLDN18.2 bispecific antibody to block the binding of human CD47 to the receptor SIRPα in hCLDN18.2-NUGC-4 cells. [Figure 5ab] FIG. 1 shows the inhibitory effect of anti-CD47-CLDN18.2 bispecific antibody on tumor growth in mice. [Figure 6] FIG. 1 shows the ADCP activity of anti-CD47-CLDN18.2 bispecific antibodies measured by a bioluminescence reporter gene. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] definition In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. And the terms related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology, and laboratory operation procedures used herein are terms and common procedures widely used in the corresponding fields. In addition, in order to better understand the present invention, the following provides definitions and interpretations of related terms.

[0016] As used herein, the terms "comprise," "include," "contain," and "have" are open-ended and refer to the inclusion of the recited elements, steps, or components, but not the exclusion of other elements, steps, or components that are not recited. The term "consisting of" does not include any elements, steps, or components that are not specified. The term "consisting essentially of" refers to the scope being limited to the specified elements, steps, or components, as well as optionally present elements, steps, or components that do not significantly affect the basic and novel characteristics of the claimed subject matter. It should be understood that the terms "consisting essentially of" and "consisting of" are covered by the meaning of the term "comprising."

[0017] As used herein, "antibody" refers to an immunoglobulin or fragment thereof, which specifically binds to an antigen epitope through at least one antigen-binding site. In this specification, the definition of antibody covers antigen-binding fragments. The term "antibody" includes multispecific antibodies (e.g., bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, single domain antibodies, and antigen-binding fragments. Antibodies may be synthetic (e.g., produced by chemical or bioconjugation), enzymatically derived, or recombinantly produced. Antibodies according to this specification include any immunoglobulin type (e.g., IgG, IgM, IgD, IgE, IgA, and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass (e.g., IgG2a and IgG2b). An antibody may be a "monovalent," "bivalent," "trivalent," or "tetravalent" or higher antibody, indicating that it contains one, two, three, four or more antigen-binding sites.

[0018] As used herein, a "full-length antibody" typically comprises four polypeptides: two heavy chains (HC) and two light chains (LC). Each light chain comprises, from the N-terminus (amino acid terminus) to the C-terminus (carboxyl terminus), a "light chain variable region (VL)" and a "light chain constant region (CL)". Each heavy chain comprises, from the N-terminus to the C-terminus, a "heavy chain variable region (VH)" and a "heavy chain constant region (CH)". In general, the heavy chain constant region of a full-length antibody may comprise, from the N-terminus to the C-terminus, CH1-hinge region-CH2-CH3. In some immunoglobulin types (e.g., IgM and IgE), the heavy chain constant region may comprise, from the N-terminus to the C-terminus, CH1-hinge region-CH2-CH3-CH4.

[0019] The light chain variable region and the heavy chain variable region may each comprise three highly variable "complementarity determining regions (CDRs)" and four relatively conserved "framework regions (FRs)", and are linked from N-terminus to C-terminus in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Herein, the CDRs (CDRLs or LCDRs) of the light chain variable region may be referred to as LCDR1, LCDR2 and LCDR3, and the CDRs (CDRHs or HCDRs) of the heavy chain variable region may be referred to as HCDR1, HCDR2 and HCDR3.

[0020] In the present invention, the amino acid sequences of the CDRs are all represented according to the AbM definition rules (sequences in the claims of the present invention are also represented according to the AbM definition rules). However, as will be appreciated by those skilled in the art, there are various ways in which the CDRs of an antibody can be defined in the art, such as by Chothia, which is based on the three-dimensional structure of the antibody and the topology of the CDR loops (see, e.g., Chothia, C. et al., Nature, 342, 877-883 (1989), and Al-Lazikani, B. et al., J. Mol. Biol., 273, 927-948 (1997)), Kabat, which is based on antibody sequence variability (see, e.g., Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242), AbM (Martin, ACR and J. Allen (2007) “Bioinformatics tools for antibody engineering,” in S. Dubel (ed.), Handbook of Therapeutic Antibodies. Weinheim: Wiley-VCH Verlag, pp. 95-118), Contact (MacCallum, RM et al., (1996) J. Mol. Biol. 262:732-745), IMGT (see Lefranc, M.-P., 2011 (6), IMGT, the International ImMunoGeneTics Information System Cold Spring Harb Protoc., and Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003)), and the North CDR definition based on affinity propagation clustering utilizing multiple crystal structures.As will be understood by those skilled in the art, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof (e.g., variable region) should be understood to cover the complementarity determining regions defined by any one of the above known schemes described in the present invention. Although the scope of what is claimed in the claims of the present invention is the sequence shown based on the AbM definition rules, corresponding amino acid sequences based on other CDR definition rules also fall within the scope of protection of the present invention.

[0021] Therefore, when an antibody is defined by a specific CDR sequence defined in the present invention, the scope of said antibody further covers antibodies whose variable region sequences include said specific CDR sequences, but whose described CDR boundaries differ from the specific CDR boundaries defined in the present invention due to the application of a different scheme (e.g. a different assignment system rule or combination).

[0022] As used herein, the terms "framework region" and "framework region" are used interchangeably. As used herein, the terms "framework region", "framework region" or "FR" residues refer to those amino acid residues in an antibody variable region outside the CDR sequences defined above.

[0023] As used herein, a "single domain antibody (sdAb)" or "nanobody" refers to an antibody that comprises a single immunoglobulin variable domain (single variable domain) as a functional antigen-binding fragment. Analogous to the variable regions of a full-length antibody, a single variable domain typically comprises CDR1, CDR2 and CDR3 that form the antigen-binding site and framework regions that perform a supporting function. A single variable domain may be, for example, a variable domain of a heavy-chain antibody (VHH), a shark IgNAR variable domain, a human light chain antibody variable domain and a heavy chain antibody variable domain.

[0024] As used herein, "antibody-dependent cell-mediated phagocytosis" or "ADCP" refers to a cell-mediated process in which non-specific cytotoxic cells expressing Fc gamma receptors (FcγR) (e.g., monocytes, macrophages, neutrophils, and dendritic cells) recognize antibodies bound to target cells (e.g., tumor cells) and subsequently phagocytose the target cells (e.g., tumor cells) as effector cells. In some embodiments, the anti-CD47-CLDN18.2 bispecific antibodies of the invention mediate ADCP against cancer cells expressing CLDN18.2 (particularly those expressing CD47 and CLDN18.2).

[0025] As used herein, "percent (%) sequence identity" of amino acid sequences, "sequence identity" has a definition well known in the art and refers to the percent identity between two polypeptide sequences determined by sequence alignment (e.g., manual inspection or well-known algorithms). It can be determined using methods well known to those skilled in the art, for example, publicly available computer software such as BLAST, BLAST-2, Clustal Omega and FASTA software.

[0026] As used herein, an amino acid sequence "from" or "derived from" a reference amino acid sequence is the same as or homologous to part or all of the reference amino acid sequence. For example, an amino acid sequence derived from a human immunoglobulin heavy chain constant region may have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the wild-type sequence of the human immunoglobulin heavy chain constant region from which it is derived.

[0027] Non-essential regions in a polypeptide (e.g., CDR regions of an antibody, non-essential amino acids in framework regions, amino acids in constant regions) can be modified, for example, by substitution, addition, and / or deletion of one or more amino acids, without changing the function of the polypeptide. As can be understood by those skilled in the art, amino acids in non-essential areas in a polypeptide can be substituted with suitable conservative amino acids and generally do not change its biological activity (see, for example, Watson et al., Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub. co., p.224). Suitable conservative substitutions are well known to those skilled in the art. In some cases, the amino acid substitution is a non-conservative substitution. As can be understood by those skilled in the art, amino acid mutations or modifications can be made to an antibody or antibody fragment to change its properties, for example, to change the type of antibody glycosylation modification, to change the ability to form interchain disulfide bonds, or to provide active groups for the preparation of antibody conjugates. Antibodies or antigen-binding fragments thereof containing such amino acid mutations or modifications also fall within the scope of the bispecific antibodies of the present invention.

[0028] The anti-CD47-CLDN18.2 bispecific antibody of the invention or the polynucleotide encoding same may be isolated. As used herein, the term "isolated" refers to a material (e.g., a polynucleotide or polypeptide) that has been separated from the source or environment in which it is found, i.e., is substantially free of any other components.

[0029] As used herein, the terms "polynucleotide" and "nucleic acid" are used interchangeably to refer to an oligomer or polymer comprising at least two linked nucleotides or nucleotide derivatives, and may generally include deoxyribose nucleic acid (DNA) and ribose nucleic acid (RNA).

[0030] As used herein, a "vector" is a vehicle for introducing an exogenous polynucleotide into a host cell, and when the vector is transformed into a suitable host cell, the exogenous polynucleotide can be amplified or expressed. A vector usually remains free, but can also be designed to integrate a gene or a part thereof into a chromosome of a genome. As used herein, the definition of vector covers plasmids, linearized plasmids, viral vectors, cosmids, phage vectors, phagemids, artificial chromosomes (e.g., yeast artificial chromosomes and mammalian artificial chromosomes), and the like. Viral vectors include, but are not limited to, retroviral vectors (including lentiviral vectors), adenoviral vectors, adeno-associated viral vectors, herpes viral vectors, pox viral vectors, and baculoviral vectors, and the like.

[0031] As used herein, the term "expression" refers to the production of RNA and / or polypeptides.

[0032] As used herein, "expression vector" refers to a vector capable of expressing a polynucleotide of interest (including DNA and RNA). For example, in an expression vector, a polynucleotide sequence (including DNA and RNA) encoding a polypeptide of interest can be operably linked to a regulatory sequence (e.g., a promoter and a ribosome binding site) capable of influencing the expression of the polynucleotide sequence. The regulatory sequence may include a promoter and a terminator sequence, and may optionally include an origin of replication, a selection marker, an enhancer, an adenylation signal, and the like. The expression vector may be a plasmid, a phage vector, a recombinant virus, or other vector, which, when introduced into a suitable host cell, causes the expression of the polynucleotide of interest. Suitable expression vectors are well known to those skilled in the art. Those skilled in the art can prepare an expression vector as needed, which is replicable in a host cell, and which remains free in the host cell or is integrated into the host cell genome.

[0033] As used herein, a "host cell" is a cell for receiving, maintaining, replicating or amplifying a vector. A host cell may be used to express a polynucleotide or a polypeptide encoded by a vector. A host cell may be a eukaryotic or prokaryotic cell. Prokaryotic cells, such as E. coli or Bacillus subtilis, fungal cells, such as yeast cells or Aspergillus, insect cells (e.g., S2 Drosophila cells or Sf9) and animal cells (e.g., fibroblasts, CHO cells, COS cells, HeLa cells, NSO cells or HEK293 cells).

[0034] As used herein, the term "treatment" refers to an improvement to a disease / symptom, e.g., reducing or eliminating the disease / symptom, preventing or slowing the onset, progression and / or worsening of the disease / symptom. Thus, treatment includes prophylaxis, treatment and / or cure.

[0035] As used herein, the term "pharmaceutical acceptable carrier agent" refers to a carrier agent that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, and is known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusting agents, surfactants, adjuvants, ionic strength enhancing agents, diluents, agents that maintain osmolarity, agents that delay absorption, and preservatives. For example, pH adjusting agents include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, e.g., Tween-80. Ionic strength enhancing agents include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, e.g., parabens, trichlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmolarity include, but are not limited to, sugars, sodium chloride, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffer solutions (e.g., buffered saline), ols and polyols (e.g., glycerol), and the like. Preservatives include various antibacterial and antifungal agents, such as, but not limited to, thimerosal, 2-phenoxyethanol, parabens, trichlorobutanol, phenol, sorbic acid, and the like. The stabilizer has the meaning commonly understood by those skilled in the art and is capable of stabilizing the desired activity of the active ingredient in the pharmaceutical product, and includes, but is not limited to, sodium glutamate, gelatin, SPGA (Sucrose-Phosphate-Glutamate-Albumin), sugars (e.g., sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (e.g., glutamic acid, glycine), proteins (e.g., dried whey, albumin, or casein) or their degradation products (e.g., lactalbumin hydrolysate), and the like.

[0036] As used herein, examples of mammals include, but are not limited to, humans, non-human primates, rats, mice, cows, horses, pigs, sheep, alpacas, dogs, cats, etc. As used herein, the term "subject" refers to a mammal, e.g., a human. In some embodiments, the subject is a human. In some embodiments, the subject is a cancer patient, a human or animal suspected of or at risk of suffering from cancer.

[0037] Anti-CD47-CLDN18.2 bispecific antibody

[0038] The present invention provides an anti-CD47-CLDN18.2 bispecific antibody, comprising a first antigen-binding portion that binds CD47 and a second antigen-binding portion that binds CLDN18.2, wherein the first antigen-binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VL); The heavy chain variable region comprises: 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO:4 or a variant thereof; 2) HCDR2 comprising the amino acid sequence of SEQ ID NO:5 or a variant thereof; 3) an HCDR3 comprising the amino acid sequence of SEQ ID NO:6 or a variant thereof; and The light chain variable region comprises: 1) an LCDR1 comprising the amino acid sequence of SEQ ID NO:7 or a variant thereof; 2) an LCDR2 comprising the amino acid sequence of SEQ ID NO:8 or a variant thereof; 3) an LCDR3 comprising the amino acid sequence of SEQ ID NO:9 or a variant thereof; Here, the variant has one or two amino acid substitutions, additions and / or deletions compared to the sequence from which it is derived.

[0039] In one specific embodiment, the first antigen-binding portion comprises a first antigen-binding portion that specifically binds to CD47, said first antigen-binding portion comprising a heavy chain variable region (VH) and a light chain variable region (VL); The heavy chain variable region comprises: 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO:4; 2) an HCDR2 comprising the amino acid sequence of SEQ ID NO:5; 3) an HCDR3 comprising the amino acid sequence of SEQ ID NO:6; and The light chain variable region comprises: 1) an LCDR1 comprising the amino acid sequence of SEQ ID NO:7; 2) an LCDR2 comprising the amino acid sequence of SEQ ID NO:8; 3) an LCDR3 comprising the amino acid sequence of SEQ ID NO:9.

[0040] In some embodiments, the VH comprises 1) an amino acid sequence of SEQ ID NO:10, or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to SEQ ID NO:10, and / or The VL comprises 1) the amino acid sequence of SEQ ID NO:11, or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:11.

[0041] In some embodiments, the VH comprises the amino acid sequence of SEQ ID NO:10, and the VL comprises the amino acid sequence of SEQ ID NO:11.

[0042] The first antigen-binding moiety may comprise any form of antigen-binding fragment, for example, scFv, dsFv, scdsFv, Fab, Fab' or F(ab')2. According to the present invention, the first antigen-binding moiety specifically binds to CD47 on the surface of cancer cells, but does not or does not substantially bind to CD47 on red blood cells, such that the bispecific antibody of the present invention does not cause hemagglutination.

[0043] The second antigen-binding moiety may comprise any form of antigen-binding fragment, including, but not limited to, scFv, dsFv, scdsFv, Fab, Fab', F(ab')2 and single variable domains. In some embodiments, the second antigen-binding moiety comprises an immunoglobulin single variable domain that specifically binds to CLD18.2. Immunoglobulin single variable domains that specifically bind to CLD18.2 are described, for example, in CN112480248A and WO 2020238730A1, the entire contents of which are incorporated herein by reference. In some embodiments, the immunoglobulin single variable domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:13 or a variant thereof, a CDR2 comprising the amino acid sequence of SEQ ID NO:14 or a variant thereof, and a CDR3 comprising the amino acid sequence of SEQ ID NO:15 or a variant thereof, wherein the variant has one or two amino acid substitutions, additions and / or deletions compared to the sequence from which it is derived. In one specific embodiment, the immunoglobulin single variable domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:13, a CDR2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR3 comprising the amino acid sequence of SEQ ID NO:15. In some embodiments, the immunoglobulin single variable domain comprises the amino acid sequence of SEQ ID NO:12. In further embodiments, the immunoglobulin single variable domain comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the amino acid sequence of SEQ ID NO:12.

[0044] In some embodiments, the first antigen-binding moiety and the second antigen-binding moiety are linked via a linker. The linker may be a peptide linker or a chemical bond, and is preferably a linker. Exemplary peptide linkers are polyglycine (G), polyalanine (A), polyserine (S) or combinations thereof, such as GGAS, GGGS, GGGSG, or (G4S). n where n is an integer from 1 to 20. Preferably, n is an integer from 1 to 5. In one specific embodiment, the peptide linker comprises the amino acid sequence of SEQ ID NO:22 or SEQ ID NO:23.

[0045] In some embodiments, the anti-CD47-CLDN18.2 bispecific antibody of the invention further comprises an immunoglobulin constant region. The immunoglobulin constant region may be the heavy chain constant region (CH) and the light chain constant region (CL) of any species of immunoglobulin. The heavy chain constant region may be derived from the heavy chain constant region of any subtype (e.g., IgA, IgD, IgE, IgG, and IgM), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (e.g., IgG2a and IgG2b) of immunoglobulin, or a combination thereof. In a preferred embodiment, the heavy chain constant region may comprise at least an Fc region, for example, the heavy chain constant region of IgG1 may comprise all or a portion of the hinge region-CH2-CH3 or CH1-hinge region-CH2-CH3. The light chain constant region may be derived from a λ (Lambda) light chain or a κ (Kappa) light chain constant region. In one preferred embodiment, the heavy chain constant region is a human IgG1 heavy chain constant region. In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:2. In one preferred embodiment, the light chain constant region is a human kappa light chain constant region. In some embodiments, the light chain constant region comprises the amino acid sequence of SEQ ID NO:3.

[0046] In some embodiments, the VH and VL of a first antigen-binding moiety are fused to the N-terminus of the heavy chain constant region and the light chain constant region, respectively, and a single variable domain of a second antigen-binding moiety is fused, optionally via a linker, to the N-terminus of the VH, the N-terminus of the VL, the C-terminus of the heavy chain constant region or the C-terminus of the light chain constant region.

[0047] In some embodiments, the anti-CD47-CLDN18.2 bispecific antibody comprises a first polypeptide and a second polypeptide, the first polypeptide comprising a VH and a heavy chain constant region of a first antigen-binding moiety, the second polypeptide comprising a VL and a light chain constant region of a first antigen-binding moiety, and a single variable domain of a second antigen-binding moiety, optionally fused to the N-terminus of the VH or VL or to the C-terminus of the heavy chain constant region or the light chain constant region via a linker. In some embodiments, a single variable domain is optionally fused to the N-terminus of the VH or to the C-terminus of the heavy chain constant region via a linker, and the first polypeptide may also be referred to as a fused heavy chain. In some embodiments, a fused heavy chain has the structure of formula (I) or formula (III) as set forth below. In another embodiment, a single variable domain of a second antigen-binding moiety is optionally fused to the N-terminus of the VL or to the C-terminus of the light chain constant region via a linker, and the second polypeptide may also be referred to as a fused light chain. In some embodiments, the fusion light chain has the structure of Formula (IV) or Formula (VI) shown below.

[0048] In some embodiments, the first polypeptide has the structure of Formula (I): VH-CH-Linker-VHH formula (I), The second polypeptide has the structure (II): VL-CL formula (II), Where: VH and VL are the heavy and light chain variable regions, respectively, of the first antigen-binding portion described above; VHH is an immunoglobulin single variable domain as described above, CH and CL are the heavy chain constant region and the light chain constant region, respectively, as described above; Linker is a linker.

[0049] In some embodiments, the first polypeptide has a structure of Formula (I), which comprises the amino acid sequence of SEQ ID NO:20, and the second polypeptide has a structure of Formula (II), which comprises the amino acid sequence of SEQ ID NO:17.

[0050] In some embodiments, the first polypeptide has the structure of Formula (III): VHH-Linker-VH-CH formula (III), The second polypeptide has a structure of formula (II): Where: VHH is an immunoglobulin single variable domain as described above, VH is the heavy chain variable region of the first antigen-binding portion described above; CH is the heavy chain constant region described above, Formula (II) is as described above, Linker is a linker.

[0051] In some embodiments, the first polypeptide has a structure of Formula (III), which comprises the amino acid sequence of SEQ ID NO:16, and the second polypeptide has a structure of Formula (II), which comprises the amino acid sequence of SEQ ID NO:17.

[0052] In some embodiments, the first polypeptide has a structure of formula (III), which comprises the amino acid sequence of SEQ ID NO:21, and the second polypeptide has a structure of formula (II), which comprises the amino acid sequence of SEQ ID NO:17.

[0053] In a further embodiment, the first polypeptide has the structure of Formula (III) and the second polypeptide has the structure of Formula (IV): VHH-Linker-VL-CL formula (IV), Where: Formula (III) is as described above, VHH is an immunoglobulin single variable domain as described above, VL is the light chain variable region of the first antigen-binding portion described above, CL is the light chain constant region described above, Linker is a linker.

[0054] In some embodiments, the first polypeptide has a structure of formula (III), which comprises the amino acid sequence of SEQ ID NO:16, and the second polypeptide has a structure of formula (IV), which comprises the amino acid sequence of SEQ ID NO:19.

[0055] In another embodiment, the first polypeptide has the structure of Formula (V): VH-CH formula (V), The second polypeptide has the structure of formula (IV): Where: Formula (IV) is as described above, VH is the heavy chain variable region of the first antigen-binding portion described above; CH is the heavy chain constant region described above, Linker is a linker.

[0056] In some embodiments, the first polypeptide has a structure of formula (V), which comprises the amino acid sequence of SEQ ID NO:18, and the second polypeptide has a structure of formula (IV), which comprises the amino acid sequence of SEQ ID NO:19.

[0057] In another embodiment, the first polypeptide has the structure of Formula (V) and the second polypeptide has the structure of Formula (VI): VL-CL-Linker-VHH formula (VI), Where: Formula (V) is as described above, VHH is an immunoglobulin single variable domain as described above, VL is the light chain variable region of the first antigen-binding portion described above, CL is the light chain constant region described above, Linker is a linker.

[0058] In some embodiments, the anti-CD47-CLDN18.2 bispecific antibody of the invention comprises: 1) Blocks the binding of CD47 on the surface of cancer cells to SIRPα, 2) Induce phagocytosis by macrophages of cancer cells expressing CD47 and CLDN18.2, and / or 3) It can bind to cancer cells expressing CD47 and CLDN18.2, but not or substantially not bind to red blood cells.

[0059] Polynucleotides, Vectors and Host Cells

[0060] In another aspect, the present invention provides an isolated polynucleotide, comprising a polynucleotide sequence encoding an anti-CD47-CLDN18.2 bispecific antibody of the present invention.

[0061] The polynucleotides of the present invention can be obtained using methods known in the art, such as phage display libraries, yeast display libraries, immunized animals, isolation from immortalized cells (e.g., mouse B cell hybridoma cells, EBV-mediated immortalized B cells), or chemical synthesis. The polynucleotides of the present invention can be codon-optimized for the host cell for expression.

[0062] In a further aspect, the invention further comprises a vector comprising the polynucleotide of the invention. In some embodiments, the polynucleotide of the invention is cloned into an expression vector. The expression vector may further comprise additional polynucleotide sequences, such as regulatory sequences and antibiotic resistance genes. The expression vector may further comprise a polynucleotide sequence encoding an additional polypeptide. The additional polypeptide may be, for example, a polypeptide that facilitates detection and / or isolation of the antibody or antigen-binding fragment, including, but not limited to, an affinity tag (e.g., polyhistidine tag (His6) or glutathione S-transferase (GST) tag), a polypeptide comprising a protease cleavage site, and a reporter protein (e.g., a fluorescent protein).

[0063] In some embodiments, the polynucleotide of the present invention is produced as a recombinant nucleic acid. Recombinant nucleic acid can be produced using techniques well known in the art, such as chemical synthesis, DNA recombinant technology (e.g., polymerase chain reaction (PCR) technology), etc. (see Sambrook, J., EF Fritsch, and T. Maniatis. (1989). Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0064] The polynucleotides of the present invention may be present in one or more expression vectors. In some embodiments, the expression vector is a DNA plasmid, for example, for expression in bacteria, yeast or mammalian cells. In other embodiments, the expression vector is a viral vector. In other embodiments, the expression vector is a phage vector or a phagemid vector.

[0065] The present invention further includes a host cell, which comprises at least one polynucleotide or vector as described above. The polynucleotide or expression vector of the present invention can be introduced into a suitable host cell using various methods known in the art. Such methods include, but are not limited to, liposome transfection, electroporation, viral transduction, and calcium phosphate transfection.

[0066] In a preferred embodiment, the host cell is for expressing the anti-CD47-CLDN18.2 bispecific antibody of the present invention. Examples of host cells include, but are not limited to, prokaryotic cells (e.g., bacteria, e.g., E. coli) and eukaryotic cells (e.g., yeast, insect cells, mammalian cells).

[0067] Suitable mammalian host cells for expressing antibodies include, but are not limited to, myeloma cells, HeLa cells, HEK cells (e.g., HEK 293 cells), Chinese hamster ovary (CHO) cells and other mammalian cells suitable for expressing antibodies.

[0068] The present invention further provides a method for producing an anti-CD47-CLDN18.2 bispecific antibody of the present invention, comprising: (I) culturing a host cell of the invention under suitable conditions to express the anti-CD47-CLDN18.2 bispecific antibody; (II) isolating the antibody from the host cell or a culture thereof.

[0069] In some embodiments, a single vector is used, which contains polynucleotide sequences encoding the heavy and light chains. In some embodiments, two vectors are used, where one vector encodes the light chain of the antibody and the other encodes the heavy chain of the antibody. In some embodiments, the host cell further comprises a partner plasmid, which helps to improve the solubility, stability and / or folding of the antibody. Techniques for isolating and purifying antibodies from host cells or their medium are well known to those of skill in the art.

[0070] Antibody conjugates

[0071] The present invention further provides an antibody conjugate, which comprises an anti-CD47-CLDN18.2 bispecific antibody of the present invention conjugated to at least one therapeutic agent. An antibody-drug conjugate (ADC) is an exemplary antibody conjugate, where the therapeutic agent may be, for example, a cytotoxic agent.

[0072] As used herein, "conjugation" refers to two or more moieties being linked together by covalent or non-covalent interactions. In a preferred embodiment, the conjugation is a covalent conjugation.

[0073] The therapeutic agent may be selected from cytotoxic drugs, therapeutic antibodies (e.g., antibodies or antigen-binding fragments thereof that specifically bind to another antigen), radioisotopes, oligonucleotides and their analogs (e.g., interfering RNA), bioactive peptides, protein toxins (e.g., diphtheria toxin, ricin), and enzymes (e.g., urease).

[0074] A cytotoxic agent refers to a substance that inhibits or reduces the activity, function, and / or kills cells. Examples of cytotoxic drugs include maytansinoids (e.g., maytansine), auristatins (e.g., MMAF, MMAE, MMAD), duostatins, cryptophycin, vinca alkaloids (e.g., vinblastine, vincristine), colchicines, dolostatins, taxanes, paclitaxel, docetaxel, cabazitaxel, enediyne antibiotics, cytochalasins, camptothecins, anthracycline antibiotics (e.g., daunorubicin, dihydroxyanthracindione, doxorubicin), cytotoxic antibiotics (e.g., mitomycin, actinomycin, duocal, These include, but are not limited to, duocarmycin (e.g., CC-1065), auromycin, duomycin, calicheamicin, endomycin, phenomycin), doxorubicin, daunorubicin, calicheamicin, cisplatin, ethidium bromide, zeocin, mitomycin, mithramycin, pladienolide, podophyllotoxin, etoposide, mitoxantrone, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine, nelarabine, carmustine, lomustine, methotrexate, melphalan, tenoposide, glucocorticoids, and the like.

[0075] Radioisotopes can be, for example, 212 Bi, 213 Bi, 131 I, 125 I, 111 In, 177 Lu, 186 Re,188 Re, 153 Sm, 90 Y. Antibodies labeled with radioisotopes may also be referred to as radioimmunoconjugates.

[0076] In a preferred embodiment, the biologically active polypeptide is a polypeptide or protein having therapeutic activity, binding activity or enzymatic activity. Non-limiting examples of biologically active polypeptides include, but are not limited to, protein toxins (e.g., diphtheria toxin, ricin), enzymes (e.g., urease, horseradish peroxidase), and cytokines.

[0077] In some embodiments, the therapeutic agent is a molecule with biological antitumor activity. Molecules with biological antitumor activity include, but are not limited to, cytotoxic agents, chemotherapeutic agents, radioisotopes, immune checkpoint inhibitors, antibodies targeting tumor-specific antigens, and other antitumor drugs. In one preferred embodiment, the therapeutic agent is a cytotoxic agent. In a further preferred embodiment, the therapeutic agent is a radioisotope.

[0078] Therapeutic agents can be conjugated to the anti-CD47-CLDN18.2 bispecific antibodies of the present invention via a linker using any technique known in the art. The linker may contain an active group for covalent conjugation, such as an amine, a hydroxylamine, a maleimide group, a carboxyl group, a phenyl group, a thiol, a sulfhydryl group, or a hydroxyl group. The linker may be cleavable or non-cleavable. A cleavable linker is, for example, an enzyme-cleavable linker (e.g., a peptide containing a protease cleavage site), a pH-sensitive linker (e.g., a hydrazone linker), or a reducible linker (e.g., a disulfide bond).

[0079] In some embodiments, the linker comprises an active group selected from an amine, a hydroxylamine, a maleimide group, a carboxyl group, a phenyl group, a thiol, a sulfhydryl group, and a hydroxy group. In some embodiments, the linker is a chemical bond. In some embodiments, the linker comprises an amino acid or a peptide of 2 to 10 amino acids. The amino acid may be a natural or unnatural amino acid.

[0080] In some embodiments, the therapeutic agent is conjugated to a linker to form an intermediate prior to conjugation with the anti-CD47-CLDN18.2 bispecific antibody of the invention. In some embodiments, the intermediate is linked by forming a thioether bond with a sulfhydryl group of the anti-CD47-CLDN18.2 bispecific antibody of the invention. The structure and methods of making such intermediates, as well as methods of using them to make antibody conjugates, are described, for example, in International Patent Application Publication No. WO 2019114666, the entire relevant content of which is incorporated herein by reference.

[0081] Drug Compositions

[0082] The present invention further provides a pharmaceutical composition, which comprises an anti-CD47-CLDN18.2 bispecific antibody or antibody conjugate of the present invention and a pharma- ceutically acceptable carrier agent.

[0083] Pharmaceutically acceptable carrier agents include diluents, adhesives and glues, lubricants, disintegrants, preservatives, vehicles, dispersants, flow agents, sweeteners, coatings, excipients, preservatives, antioxidants (e.g., ascorbic acid, cysteine ​​hydrochloride, sodium hydrogen sulfate, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, The additives may include, but are not limited to, agents such as tartrates, tartaric acid, phosphoric acid, etc., solubility enhancers, gelling agents, softeners, solvents (e.g., water, alcohol, acetic acid, and syrup), buffers (e.g., phosphate buffers, histidine buffers, and acetate buffers), surfactants (e.g., non-ionic surfactants such as polysorbate 80, polysorbate 20, poloxamer, or polyethylene glycol), antibacterial agents, antifungal agents, isotonicity agents (e.g., trehalose, sucrose, mannitol, sorbitol, lactose, glucose), absorption delaying agents, chelating agents, and emulsifying agents. For compositions comprising an antibody or antibody conjugate, a suitable carrier agent may be selected from a buffer (e.g., citrate buffer, acetate buffer, phosphate buffer, histidine buffer, histidine salt buffer), an isotonicity agent (e.g., trehalose, sucrose, mannitol, sorbitol, lactose, glucose), a non-ionic surfactant (e.g., polysorbate 80, polysorbate 20, poloxamer), or a combination thereof.

[0084] The pharmaceutical compositions according to the present invention may be in various dosage forms, including but not limited to solid, semi-solid, liquid, powder or lyophilized forms. Preferably, the pharmaceutical compositions are suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). For compositions containing antibodies or antibody conjugates, the preferred dosage forms may typically be, for example, injectable solutions and lyophilized powders.

[0085] The pharmaceutical composition according to the present invention can be administered to a subject by any method known in the art, for example, systemic or local administration. The route of administration includes, but is not limited to, parenteral (e.g., intravenous, intraperitoneal, intradermal, intramuscular, intradermal or intracavitary), topical (e.g., intratumoral), epidural or mucosal (e.g., intranasal, oral, vaginal, rectal, sublingual or topical). As can be understood by those skilled in the art, the exact dosage depends on various factors, such as the metabolic kinetic properties of the pharmaceutical composition, the duration of treatment, the excretion rate of the particular compound, the purpose of the treatment, the route of administration and the condition of the subject, such as the patient's age, health, weight, sex, diet, medical history, and other factors known in the medical art. The method of administration can be, for example, injection or infusion.

[0086] As a general guideline, the dosage range of the anti-CD47-CLDN18.2 bispecific antibodies of the invention may be about 0.0001-100 mg / kg, more typically 0.01-20 mg / kg body weight of the subject. For example, the dosage may be 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight, 10 mg / kg body weight or 20 mg / kg body weight, or within the range of 1-20 mg / kg. Exemplary treatment schemes include weekly, biweekly, triweekly, quadruple, monthly, trimonthly, 3-6 month dosing, or shorter dosing intervals at the beginning and longer dosing intervals at later times. The dosing regimen may be intravenous infusion.

[0087] treatment

[0088] In a further aspect, the present invention relates to the use of an anti-CD47-CLDN18.2 bispecific antibody, antibody conjugate or pharmaceutical composition of the invention in the manufacture of a medicament for treating a disease in a subject.

[0089] The present invention further relates to an anti-CD47-CLDN18.2 bispecific antibody, antibody conjugate or pharmaceutical composition of the invention, which is used for treating a disease.

[0090] The present invention further provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of an anti-CD47-CLDN18.2 bispecific antibody, antibody conjugate or pharmaceutical composition of the present invention.

[0091] In some embodiments, the disease described above is cancer. As used herein, "cancer" includes, but is not limited to, blood cancer and solid tumors. The cancer may further be a metastatic cancer. "Metastasis" refers to the spread of cancer cells from their original site to other parts of the body. For example, anti-CD47-CLDN18.2 bispecific antibodies may be used to treat CLDN18.2 positive cancers. In a preferred embodiment, the anti-CD47-CLDN18.2 bispecific antibodies are for treating CD47 and CLDN18.2 positive cancers. In some embodiments, the cancer is gastric cancer.

[0092] kit

[0093] The present invention further provides a kit, comprising an anti-CD47-CLDN18.2 bispecific antibody, antibody conjugate or pharmaceutical composition of the invention, and instructions. The kit may further comprise a suitable container. In some embodiments, the kit further comprises an administration device. Typically, the kit further comprises a label, which is for indicating the intended use and / or method of use of the kit contents. The term "label" includes any written or recorded material on or provided with the kit or otherwise provided with the kit.

[0094] Effect of the Invention The anti-CD47-CLDN18.2 bispecific antibody of the present invention can achieve at least one of the following beneficial effects: 1) Blocks the binding of CD47 on the surface of cancer cells to SIRPα, 2) Induce phagocytosis by macrophages of cancer cells expressing CD47 and CLDN18.2, 3) mediate ADCP against cancer cells expressing CLDN18.2; 4) It binds to cancer cells expressing CD47 and CLDN18.2, but does not or does not substantially bind to red blood cells.

[0095] Furthermore, compared with monoclonal antibodies that target only CD47, the anti-CD47-CLDN18.2 bispecific antibody of the present invention has higher binding activity to CD47- and CLDN18.2-positive tumor cells and a stronger blocking effect on the interaction between CD47 and SIRPα. Working Example

[0096] The following examples are intended to be merely illustrative of the present invention and should not be construed as limiting the present invention in any manner. Materials and Methods 1. Construction of antibody expression plasmids

[0097] The DNA fragments encoding the antibody heavy and light chains were produced by DNA recombination technology and then cloned into the expression vector pcDNA3.4-TOPO (Invitrogen) to obtain the antibody heavy and light chain expression plasmids. They were amplified in E. coli DH5α, and then the antibody heavy and light chain expression plasmids were extracted and purified. 2. Antibody Expression and Purification

[0098] All antibodies were expressed (see WO 2020238730A1) using the ExpiCHO transient expression system (Thermo Fisher, A29133) and affinity purified using MabSelect SuRe LX (GE, 17547403). 3. Identification of antibody purity by SDS-PAGE

[0099] Preparation of reducing solution: 2 μg of the detection target antibody or IPI (Ipilimlumab, see below) was added to 5×SDS sampling buffer (containing DTT at a final concentration of 5 mM), heated in a 100°C dry bath for 10 min, cooled to room temperature, centrifuged at 12000 rpm for 5 min, and the supernatant was taken. The supernatant was added to a Bis-tris 4-15% gradient gel (Jinsir) and subjected to protein gel electrophoresis. Subsequently, the protein bands were stained with Coomassie Brilliant Blue, and after destaining, they were scanned with an EPSON V550 color scanner, and the purity of the protein bands was calculated by the peak area normalization method using ImageJ. 4. Identification of antibody purity by SEC-HPLC

[0100] The flow rate of the Agilent HPLC 1100 chromatography column (XBridge BEH SEC 3.5 μm, 7.8 mm ID × 30 cm, Waters) was set at 0.8 mL / min, the sample injection volume was 20 μL, and the wavelengths of the VWD detector were 280 nm and 214 nm. The mobile phase was 150 mmol / L phosphate buffer with a pH of 7.4, all samples were diluted to 0.5 mg / mL with the mobile phase, and the blank solution and sample solution were sampled sequentially. The proportions of high molecular weight polymers, antibody monomers, and low molecular weight substances in the samples according to the area normalization method were calculated. 5. Identification of antibody stability by differential scanning fluorescence

[0101] Differential scanning fluorimetry (DSF) can provide information about the structural stability of proteins based on the fluorescence change process in protein maps, detect conformational changes of proteins, and obtain the melting temperature (Tm) of proteins.

[0102] The antibody sample solution to be detected was prepared at 0.2 mg / mL, and PBS and IPI (Ipilimlumab; 0.2 mg / mL) were used as references. The test samples were added in triplicate at 19 μL / well to a 96-well plate (Nunc), and 1 μL of 100×SYPRO orange dye was added to each well, mixed uniformly by pipetting, and prepared on the machine. The thermal stability test of the samples was performed using an ABI 7500 FAST RT-PCR instrument, the test type was selected as melting curve, continuous mode was used, the scan temperature range was 25-95°C, the heating rate was 1%, and the equilibration was performed at 25°C for 5 min, data was collected during the heating, the reporter group was selected as "ROX", the quenching group was selected as "None", the reaction volume was 20 μL, and the temperature corresponding to the first peak and dip of the first derivative of the melting curve was determined as the melting temperature Tm of the antibody. Example 1 Design of anti-CD47-CLDN18.2 bispecific antibodies

[0103] This example describes an exemplary anti-CD47-CLDN18.2 bispecific antibody, in which the CLDN18.2 binding arm uses the anti-CLDN18.2 single domain antibody NA3S-H1 (the amino acid sequences of CDR1, CDR2 and CDR3 are shown in SEQ ID NOs:13, 14 and 15, respectively, and the amino acid sequence of the VHH is shown in SEQ ID NO:12), which specifically recognizes human CLDN18.2 but not CLDN18.1, and the CD47 binding arm uses the antigen binding domain of the anti-CD47 humanized antibody A7H3L3 (the amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs:4, 5 and 6, respectively, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs:7, 8 and 9, respectively, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:10, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:11). The antibody A7H3L3 was used as the heavy chain variable region (SEQ ID NO:11). The heavy chain variable region of the antibody A7H3L3 was fused to a human IgG1 heavy chain constant region (SEQ ID NO:2) to form the heavy chain of the antibody A7H3L3, and the light chain variable region was fused to a human kappa light chain constant region (SEQ ID NO:3) to form the light chain of the antibody A7H3L3. The anti-CLDN18.2 single domain antibody NA3S-H1 is disclosed in WO 2020238730A1, and its in vitro ADCC and CDC cell killing effects as well as tumor inhibition tests in a human CLDN18.2-HEK29T-SCID tumor transplant model all showed excellent efficacy. The humanized antibody A7H3L3 weakly binds to CD47 on red blood cells, making it an ideal candidate antibody for a bispecific antibody, and the bispecific antibody was designed to bind to CLDN18.2, allowing the anti-CD47 antibody A7H3L3 binding arm to better bind to tumor cells expressing the dual target and better block the SIRPα inhibitory signal.

[0104] Bispecific antibodies were designed based on the valency, position and linker length of the anti-CLDN18.2 single domain antibody (VHH) NA3S-H1, and five types of bispecific antibodies (B8 to B12, respectively) were designed. The structures of the exemplary bispecific antibodies are as shown in Table 1 and FIG. 1, and the corresponding amino acid sequences are provided in Table 2, where the sequence of Linker1 is GGGGSGGGGS (SEQ ID NO:22) and the sequence of Linker2 is GGGGS (SEQ ID NO:23).

[0105] [Table 1]

[0106] [Table 2] Example 2 Binding activity of anti-CD47-CLDN18.2 bispecific antibody to CD47 on erythrocytes

[0107] The binding of the bispecific antibody to erythrocytes was measured by flow cytometry. Another anti-CD47 antibody developed by the applicant, F4AM4-IgG1 (abbreviated as F4AM4 in the drawings, with the amino acid sequence of the heavy chain being SEQ ID NO:24 and the amino acid sequence of the light chain being SEQ ID NO:25), was used as a positive control antibody. F4AM4-IgG1 was selected as a positive control in this example because it showed strong binding to CD47 on erythrocytes in a series of functional validation experiments (performed before the experiments in this example were started).

[0108] The specific method is as follows. Red blood cells were separated from 1 mL of anticoagulated human blood, centrifuged, the supernatant was removed, rinsed twice with PBS, and then 1 mL of PBS was added to resuspend the red blood cells. 7The red blood cells were diluted to 0.01 mg / mL, 50 μL per well were aspirated and added to a 96-well round-bottom cell culture plate, and the gradient-diluted detection antibodies were added in equal volumes, mixed thoroughly and uniformly, and incubated at 4°C for 1 h. Then, the cells were rinsed three times with FACS buffer, 0.5 μg of PE-labeled goat anti-human IgG Fc antibody (Abcam, ab98596) was added, and incubated at 4°C for 1 h. After that, the cells were rinsed three times with FACS buffer, 200 μL of FACS buffer was added to resuspend the cells, and finally the amount of antibody bound to the red blood cells (shown as mean fluorescence intensity (MFI)) was detected by a flow cytometer (Beckman, CytoFLEX AOO-1-1102).

[0109] The binding activity of the antibodies to red blood cells is shown in Figures 2a and 2b. As shown in Figures 2a and 2b, even at a very high concentration (150 μg / mL), all anti-CD47-CLDN18.2 bispecific antibodies hardly bind to red blood cells or have very low binding activity compared to the strong binding of F4AM4-IgG1 to red blood cells, and at a high concentration (15 μg / mL), there is no significant difference in the binding of B9, B10, and B11 to red blood cells and the negative control IgG1, the specific numbers are shown in Table 3. Thus, the bispecific antibodies of the present invention have low binding activity to CD47 on red blood cells and do not substantially cause red blood cell aggregation.

[0110] [Table 3] Example 3 Binding activity of anti-CD47-CLDN18.2 bispecific antibodies on single and dual target expressing tumor cells

[0111] The binding activity of anti-CD47-CLDN18.2 bispecific antibody B10 to NUGC-4 cells (expressing endogenous CD47, purchased from BNCC seed bank, number BNCC341962) and hCLDN18.2-NUGC-4 cells (gastric cancer cell line NUGC-4 overexpressing exogenous human CLDN18.2 (amino acid sequence SEQ ID NO:1) was constructed using lentivirus transfection method, and expressing endogenous CD47) was measured by flow cytometry. For comparison, the binding activity of antibodies 1F8 (1F8 antibody in WO 2018075857A1) and F4AM4-IgG1 to these two cell lines was also measured. Human IgG1 was used as an isotype negative control.

[0112] The specific method is as follows: 1×10 5 NUGC-4 cells or hCLDN18.2-NUGC-4 cells were taken, centrifuged at low speed (300 g), the supernatant was removed, the cells at the bottom of the centrifuge tube were rinsed once with the formulated FACS buffer (1×PBS buffer containing 2% FBS by volume), and the gradient diluted detection antibody was added to the rinsed cells, incubated at 4°C for 1 h, then rinsed three times with the above FACS buffer, added 0.5 μg of PE-labeled goat anti-human IgG Fc antibody (Abcam, ab98596), incubated at 4°C for 1 h, and the cells were rinsed three times with FACS buffer and then resuspended in 200 μL of FACS buffer, and finally the amount of antibody bound to red blood cells (shown as mean fluorescence intensity (MFI)) was detected by a flow cytometer (Beckman, CytoFLEX AOO-1-1102).

[0113] The binding activity of the antibodies to NUGC-4 cells and hCLDN18.2-NUGC-4 cells is shown in Figures 3a and 3b, respectively. As shown in Figure 3a, bispecific antibody B10 has weak binding activity to tumor cells NUGC-4, slightly weaker than antibody 1F8. As shown in Figure 3b, bispecific antibody B10 has obviously better binding activity than antibody 1F8 to hCLDN18.2-NUGC-4 cells expressing both CD47 and CLDN18.2. Based on this, bispecific antibody B10 has weaker binding than 1F8 to cells expressing CD47 single target, but better binding than 1F8 to cells expressing CD47 and CLDN18.2 dual target. The results demonstrated that bispecific antibody B10 can simultaneously bind to CLDN18.2 and CD47 in tumor cells, enhancing its ability to bind to tumor cells. Example 4 Ability of anti-CD47-CLDN18.2 bispecific antibody to block binding of CD47 to SIRPα in tumor cells expressing single and dual targets

[0114] The ability of the anti-CD47-CLDN18.2 bispecific antibody to block binding of CD47 to SIRPα in NUGC-4 and hCLDN18.2-NUGC-4 cells was measured by flow cytometry. In comparison, the ability of antibodies 1F8, F4AM4-IgG1 and A7H3L3 to block binding of CD47 to SIRPα in NUGC-4 and hCLDN18.2-NUGC-4 tumor cells was also measured.

[0115] The specific method is as follows: 1×10 5NUGC-4 cells or hCLDN18.2-NUGC-4 cells were harvested and centrifuged at low speed (300 g) and the supernatant was removed. The cells at the bottom of the centrifuge tube were rinsed once with the formulated FACS buffer (1x PBS buffer containing 2% FBS), and then gradient-diluted detection antibodies were added to the rinsed cells, incubated for 1 h, the cells were rinsed twice with FACS buffer, and then 100 μL of 1 μg / mL SIRPα-mFc (ACRO, SIA-H52A8) was added, incubated for 1 h at 4°C, rinsed three times with FACS buffer, and 100 μL of PE-labeled goat anti-mouse Fc secondary antibody (Abcam, ab98742) diluted at 1:200 was added, incubated for 1 h at 4°C, centrifuged to remove the supernatant, and 200 μL of FACS buffer was added to the cells to resuspend them, and finally the amount of SIRPα-mFc bound to the cells (shown as mean fluorescence intensity (MFI)) was detected by a flow cytometer (Beckman, CytoFLEX AOO-1-1102).

[0116] The results in NUGC-4 cells are shown in Figure 4a. The antibody F4AM4-IgG1 was able to effectively block the binding of CD47 to SIRPα, and the IC 50 The IC was 0.033 μg / mL (0.226 nM), and antibody 1F8 had a weak blocking effect, with an IC 50 was 15.36 μg / mL (105.6 nM), whereas bispecific antibody B10 had little blocking capacity.

[0117] The results for hCLDN18.2-NUGC-4 cells are shown in Figure 4b, where antibody F4AM4-IgG1 still had a strong blocking capacity in these tumor cells, with IC 50 The IC value of bispecific antibody B10 was 0.056 μg / mL (0.383 nM). Compared with its blocking ability in NUGC-4 cells, the blocking ability of bispecific antibody B10 in hCLDN18.2-NUGC-4 cells was obviously improved and superior to that of antibody 1F8. The IC values ​​of B10 and 1F8 for blocking the binding of CD47 to SIRPα in hCLDN18.2-NUGC-4 cells were 50were 0.765 μg / mL (4.476 nM) and 11.98 μg / mL (82.34 nM), respectively, and the anti-CLDN18.2 single domain antibody NA3S-H1 did not have any blocking effect because it only binds to CLDN18.2. Based on this, bispecific antibody B10 has weaker blocking activity than antibody 1F8 on cells expressing the CD47 single target, but obviously superior blocking activity to antibody 1F8 on cells expressing the CD47 and CLDN18.2 dual targets, exerting a stronger ability to block the binding of CD47 to the receptor SIRPα.

[0118] The blocking ability of other bispecific antibodies in hCLDN18.2-NUGC-4 cells was further measured, and the results are shown in Figure 4c. Among bispecific antibodies B8-B12, bispecific antibody B10 had the strongest blocking activity. Example 5 In vivo tumor inhibition experiment of anti-CD47-CLDN18.2 bispecific antibody 5.1 In vivo tumor inhibition experiment 1

[0119] Six to seven week old female nude mice (16-18 g) were housed in an independent ventilated box with constant temperature and humidity, with the temperature of the breeding room being 21-24°C and the humidity being 30-53%. 6 hCLDN18.2-NUGC-4 cells were subcutaneously injected into the left axilla of nude mice (day 0) until the subcutaneous tumor-bearing volume of the mice was 300–400 mm. 3When the tumor volume reached a certain level (day 20), the mice with large tumor volume differences were removed, and randomly divided into groups (8 mice per group) according to tumor volume, which were PBS-treated, NA3S-H1 monoclonal antibody-treated group, A7H3L3 monoclonal antibody-treated group, NA3S-H1 + A7H3L3 combination-treated group, and bispecific antibody B10-treated group. Based on 5 mg / kg of NA3S-H1 monoclonal antibody, all other drugs were administered at equimolar doses, i.e., 9.4 mg / kg of A7H3L3 monoclonal antibody, 5 mg / kg of NA3S-H1 + A7H3L3 combination + 9.4 mg / kg, and 10.6 mg / kg of bispecific antibody B10. The drugs were administered twice a week, alternating between intraperitoneal injection (ip) and intravenous injection (iv). The length (mm) and width (mm) of the tumor were observed and recorded at regular intervals, and the tumor volume (V) was calculated. The calculation method was as follows:

number

number

[0120] The results of tumor inhibition by the antibodies are shown in Figure 5a and Table 4. As can be seen from the results, at this equimolar dose, the NA3S-H1 monoclonal antibody administration group showed little tumor inhibition effect, while the other groups all showed certain tumor inhibition effects, whereby the bispecific antibody B10 showed the best effect, reaching an anti-tumor rate of nearly 54.54% before day 39, and the tumor size was close to the initial tumor volume on day 20, which was superior to the results of combination administration (A7H3L3+NA3S-H1 (9.4+5 mpk)), indicating that the binding of bispecific antibody B10 to CLDN18.2 can enhance its blocking effect on the binding of CD47 to SIRPα.

[0121] [Table 4] 5.2 In vivo tumor inhibition experiment 2

[0122] The mice were randomly divided into groups (8 mice per group), into a PBS-treated group, a monoclonal antibody NA3S-H1-treated group, and a bispecific antibody B10-treated group. The first dose was administered on the day of inoculation (day 0), and the mice were administered twice a week. The NA3S-H1 monoclonal antibody was administered at 2.5 mg / kg, and the bispecific antibody B10 was administered at an equimolar dose, i.e., 5.3 mg / kg. The rest of the data was the same as in Example 5.1.

[0123] The results are shown in Figure 5b, where at this equimolar dose, the NA3S-H1 monoclonal antibody group showed a certain tumor inhibition effect, with an antitumor rate of approximately 54.99% (day 34), while all mice in the bispecific antibody B10 group had completely inhibited tumors, with an antitumor rate of approximately 100% (day 34). The results showed that the tumor inhibition effect of bispecific antibody B10 was obviously superior to that of anti-CLDN18.2 monoclonal antibody NA3S-H1. Example 6. Measurement of physicochemical properties of anti-CD47-CLDN18.2 bispecific antibodies 6.1 Purity determination by SDS-PAGE

[0124] The purity of bispecific antibody B10 was identified using reducing SDS-PAGE. The apparent relative molecular weights of the heavy and light chain main bands of bispecific antibody B10 were approximately 65 kD and 25 kD, respectively, which were consistent with the intended size, and the purity reached 90%. 6.2 Purity determination by SEC-HPLC

[0125] The monomer purity of bispecific antibody B10 was detected using SEC-HPLC. The monomer purity of bispecific antibody B10 measured by SEC-HPLC was greater than 94%. 6.3 Determination of DSF thermostability of bispecific antibody B10

[0126] The Tm value of bispecific antibody B10 was detected using the DSF method to evaluate its thermal stability. The results showed that bispecific antibody B10 had two melting peaks, the Tm value of the first peak was 69.85±0.06°C, and the Tm value of the second peak was 80.60±0.16°C, indicating that bispecific antibody B10 had good thermal stability. Example 7 ADCP activity of anti-CD47-CLDN18.2 bispecific antibody

[0127] Antibody-dependent cell-mediated phagocytosis (ADCP) is an important mechanism of action of therapeutic antibodies against virus-infected or tumor cells. This experiment evaluated the ADCP activity of the bispecific antibodies of the present invention by a bioluminescence reporter gene. The method used genetically engineered Jurkat cells (BPS Bioscience Inc., 71273) as effector cells, which stably expressed FcγRIIa receptor and luciferase (Int Immunopharmacol. 2021 Nov;100:108-112.), whose expression was driven by NFAT response elements. After recognizing the target cells, the antibody stimulated the NFAT response element in the cells by binding to FcγRIIa on the surface of the effector cells, and the NFAT response element drove the expression of luciferase. The activity of luciferase can be quantified by bioluminescence.

[0128] The samples to be detected (B10, A7H3L3, NA3S-H1) were each diluted to an initial reaction concentration of 200 nM, and then gradient diluted 2-fold to obtain 10 gradients. The diluted samples were added to a 96-well white-bottom plate, 50 μL per well, with three triplicate wells for each concentration gradient. An additional 150 μL / well of PBS solution was added to the edge wells of the 96-well white-bottom plate. Then, 5×10 5 hCLDN18.2-NUGC-4 cells (target cells) were added at 50 μL / well and incubated at room temperature for 30 min. Then, 1.5 × 10 6Effector cells at 50 μL / well were added at 100 / mL. The 96-well white-bottom plate was incubated in a 37°C 5% CO2 incubator for 6 h. Detection: The 96-well white-bottom plate was removed and left at room temperature for 30 min. The detection reagent luciferase substrate (Bio-Glo™ Luciferase Assay System Promega G7940) was added at 50 μL / well and reacted at room temperature for 5-10 min in the dark, and the luminescence intensity (expressed as relative light units (RLU)) was detected by a microplate reader. The logarithm of the antibody concentration was plotted against the RLU at the corresponding concentration, and the data was analyzed with Graphpad Prism software, and the EC 50 values ​​were calculated.

[0129] Experimental Results: As can be seen from FIG. 6 and Table 5, when the target cells were hCLDN18.2-NUGC-4 cells, the bispecific antibody B10 of the present invention showed higher ADCP activity than the anti-CD47 monoclonal antibody A7H3L3 and the anti-CLDN18.2 monoclonal antibody NA3S-H1.

[0130] [Table 5]

[0131] Although the embodiments of the present invention have been described in detail, those skilled in the art will understand that based on all the teachings disclosed herein, various modifications and changes can be made to the details, and all of these modifications are within the protection scope of the present invention. The protection scope of the present invention is provided by the appended claims and any equivalents thereof. Sequence Listing SEQ ID NO:1 Human CLDN18.2 MAVTACQGLGFVVSLIGIAGIIAATCMDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV SEQ ID NO:2 Human IgG1 heavy chain constant region ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:3 Human Kappa light chain constant region RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:4 A7H3L3 - HCDR1 GFNIKDIYIY SEQ ID NO:5 A7H3L3 - HCDR2 KIDPANGNTK SEQ ID NO:6 A7H3L3 - HCDR3 GYGSGFAY SEQ ID NO:7 A7H3L3-LCDR1 RASQDISNHLN SEQ ID NO:8 A7H3L3-LCDR2 YTSRIHS SEQ ID NO:9 A7H3L3-LCDR3 QQGYTLPFT SEQ ID NO:10 A7H3L3-VH QVQLVQSGAEVKKPGASVKVSCKASGFNIKDIYIYWVRQAPGQGLEWIGKIDPANGNTKYDQKFQGRATITADTSTNTAYLELSSLRSEDTAVYYCARGYGSGFAYWGQGTLVTVSS SEQ ID NO:11 A7H3L3-VL DIQMTQSPSSLSASVGDRVTITCRASQDISNHLNWYQQKPGKAPKLLIYYTSRIHSGVPSSFRGSGSGTDYTLTISSLQPEDIATYFCQQGYTLPFTFGSGTKLEIK SEQ ID NO:12 NA3S-H1 QVQLVESGGGLVQPGGSLRLSCAASGSIFNIPVMGWYRQAPGKQRELVAGISTGGTTNYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVLVVSGIGSTLEVWGQGTLVTVSS SEQ ID NO:13 NA3S-H1 CDR1 GSIFNIPV SEQ ID NO:14 NA3S-H1 CDR2 ISTGGTT SEQ ID NO:15 NA3S-H1 CDR3 NVLVVSGIGSTLEV SEQ ID NO:16 B8 / B11 heavy chain QVQLVESGGGLVQPGGSLRLSCAASGSIFNIPVMGWYRQAPGKQRELVAGISTGGTTNYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVLVVSGIGSTLEVWGQGTLVTVSSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGFNIKDIYIYWVRQAPGQGLEWIGKIDPANGNTKYDQKFQGRATITADTSTNTAYLELSSLRSEDTAVYYCARGYGSGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:17 Light chain of B8 / B10 / B12 DIQMTQSPSSLSASVGDRVTITCRASQDISNHLNWYQQKPGKAPKLLIYYTSRIHSGVPSSFRGSGSGTDYTLTISSLQPEDIATYFCQQGYTLPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:18 Heavy chain of B9 QVQLVQSGAEVKKPGASVKVSCKASGFNIKDIYIYWVRQAPGQGLEWIGKIDPANGNTKYDQKFQGRATITADTSTNTAYLELSSLRSEDTAVYYCARGYGSGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:19 Light chain of B9 / B11 QVQLVESGGGLVQPGGSLRLSCAASGSIFNIPVMGWYRQAPGKQRELVAGISTGGTTNYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVLVVSGIGSTLEVWGQGTLVTVSSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDISNHLNWYQQKPGKAPKLLIYYTSRIHSGVPSSFRGSGSGTDYTLTISSLQPEDIATYFCQQGYTLPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:20 Heavy chain of B10 QVQLVQSGAEVKKPGASVKVSCKASGFNIKDIYIYWVRQAPGQGLEWIGKIDPANGNTKYDQKFQGRATITADTSTNTAYLELSSLRSEDTAVYYCARGYGSGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGSIFNIPVMGWYRQAPGKQRELVAGISTGGTTNYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVLVVSGIGSTLEVWGQGTLVTVSS SEQ ID NO:21 B12 heavy chain QVQLVESGGGLVQPGGSLRLSCAASGSIFNIPVMGWYRQAPGKQRELVAGISTGGTTNYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVLVVSGIGSTLEVWGQGTLVTVSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGFNIKDIYIYWVRQAPGQGLEWIGKIDPANGNTKYDQKFQGRATITADTSTNTAYLELSSLRSEDTAVYYCARGYGSGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:22 Linker1 GGGGSGGGGGS SEQ ID NO:23 Linker2 GGGGS SEQ ID NO:24 F4AM4-IgG1 heavy chain QVQLVQSGAEVKKPGASVKMSCKASGYTFTSSVMHWVRQAPGQGLEWIGYINPYTDGTKYAQKFQGRATLTSDKSTSTAYMEFSSLRSEDTAVYYCGRPYYGTRYGSWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:25 F4AM4-IgG1 light chain DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISNLQPEDIATYYCQQGKNYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Claims

1. A bispecific antibody comprising a first antigen-binding portion that binds to CD47 and a second antigen-binding portion that binds to CLDN18.2, wherein the first antigen-binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VL); The heavy chain variable region comprises: 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO:4; 2) an HCDR2 comprising the amino acid sequence of SEQ ID NO:5; 3) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 6; and The light chain variable region comprises: 1) an LCDR1 comprising the amino acid sequence of SEQ ID NO: 7; 2) an LCDR2 comprising the amino acid sequence of SEQ ID NO:8; 3) a LCDR3 comprising the amino acid sequence of SEQ ID NO:

9.

2. the heavy chain variable region comprises 1) the amino acid sequence of SEQ ID NO:10, or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to SEQ ID NO:10; and / or the light chain variable region comprises 1) an amino acid sequence of SEQ ID NO: 11, or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 11; 2. The bispecific antibody of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 10 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:

11.

3. The second antigen-binding portion comprises an immunoglobulin single variable domain (VHH) that binds to CLDN18.2; Preferably, the immunoglobulin single variable domain comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 13; CDR2 comprising the amino acid sequence of SEQ ID NO: 14; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; More preferably, the immunoglobulin single variable domain comprises 1) the amino acid sequence of SEQ ID NO: 12, or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the amino acid sequence of SEQ ID NO:

12.

4. The bispecific antibody of any one of claims 1 to 3, wherein the first antigen-binding portion and the second antigen-binding portion are linked via a linker.

5. Further comprising an immunoglobulin heavy chain constant region (CH) and a light chain constant region (CL), Preferably, the heavy chain constant region is a human IgG1 heavy chain constant region, and / or the light chain constant region is a human κ light chain constant region; Further preferably, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 2 and / or the light chain constant region comprises the amino acid sequence of SEQ ID NO:

3.

6. comprising a first polypeptide and a second polypeptide, Where: The first polypeptide comprises, from N-terminus to C-terminus: It has a structure of VH-CH-Linker-VHH, The second polypeptide comprises, from N-terminus to C-terminus: VL-CL structure, Where: VH and VL are heavy chain variable domains and light chain variable domains, respectively, as defined in claim 1 or 2; VHH is an immunoglobulin single variable domain as defined in claim 3, CH and CL are, respectively, a heavy chain constant region and a light chain constant region as defined in claim 5; Linker is a linker, 6. The bispecific antibody of claim 5, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 20 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:

17.

7. An isolated polynucleotide encoding the bispecific antibody of any one of claims 1 to 6.

8. An expression vector comprising the polynucleotide of claim 7.

9. A host cell comprising the polynucleotide of claim 7 or the expression vector of claim 8.

10. An antibody conjugate comprising the bispecific antibody of any one of claims 1 to 6 conjugated to at least one therapeutic agent.

11. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 6 or the antibody conjugate of claim 10, and a pharma- ceutically acceptable carrier agent.

12. 12. Use of a bispecific antibody according to any one of claims 1 to 6, an antibody conjugate according to claim 10 or a pharmaceutical composition according to claim 11 in the manufacture of a medicament for treating cancer, preferably wherein said cancer is gastric cancer.

Citation Information

Patent Citations

  • Drug conjugates comprising antibodies against claudin 18.2

    WO2016165762A1

  • Novel CLDN18.2 binding molecule

    WO2020238730A1

  • Anti-claudin 18.2 / Anti-CD47 bispecific antibodies and uses thereof

    WO2021003082A1